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To analyse the clinical significance of the presence of androgen receptors (AR) in breast carcinomas, 
clinical and histological parameters of 153 primary breast carcinomas (median follow-up 46 months) 
were examined. Oestrogen (ER) and progesterone receptor (PR) levels were determined in cytosol 
preparations using enzyme immunoassay assays and in cryostat sections by immunohistochemistry. 
AR and Ki-67 levels were only determined hnmunohistochemically. Data were analysed by uni- and 
multivariate models. 94/153 (61%) breast carcinomas were ER+ PR+ AR+, while 14 cases were only 
positive for AR. All grade III tumours (n = 17) were steroid receptor negative and 14 (76%) of these 
cases demonstrated high Ki-67 values suggestive of more aggressive behaviour. Strikingly, 14 ductal 
carcinomas negative for ER and PR were positive for AR. In univariate analysis, AR as well as ER, 
tumour size, lymph node status, grade and Ki-67 proved to be significant prognostic factors for disease- 
free survival (DFS). Multivariate analysis, however, showed lymph node status, tumour size and ER 
status to be the only independent prognostic factors for DFS within this model. We conclude that 
simple histological and cell biological parameters, including AR, can be used to select high- and low- 
risk patients at the time of primary surgery and can provide valuable information on treatment options. 
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INTRODUCTION 
THE IMPORTANCE of the histological subclassification of breast 
cancer as one of the indicators for tumour aggressiveness 
is well recognised. Histological subtypes, such as tubular, 
cribriform and colloid cancers, are known to have a good 
prognosis, while not otherwise specified (NOS) ductal carci- 
nomas have a relatively poor prognosis; the lobular, medullary 
and mixed carcinomas are considered to represent an inter- 
mediate prognostic group [l-5]. Other tumour characteristics, 
such as lymph node status and histological grading, are con- 
sidered to be of major importance [ 1, 2, 5-91. The prognostic 
impact of additional parameters, such as proliferative activity 
[10-l 21 and the expression of oestrogen (ER) and progester- 
one receptors (PR), is also well established [13, 141. A 
relationship between subtypes of breast cancer and proliferat- 
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ive activity has been demonstrated in both histological 
[12, 151 and cytological material [15]. 
The clinical significance and functional role of androgen 
receptor (AR) expression in breast cancer is less well defined. 
In a previous study [16] on human breast cancer, we found a 
close relationship between AR, ER and PR expression. AR 
was detectable in 76% of the 100 cases of breast cancer 
investigated. Nine per cent of the tumours expressed AR as 
the only sex steroid receptor. As various studies [17, 181 
have reported that the combined use of androgen and anti- 
oestrogen therapy has therapeutic advantages over anti-oes- 
trogen treatment alone, AR determination may give additional 
information regarding the response to different endocrine 
treatment modalities. 
In this study, we report on the prognostic impact of the 
aforementioned tumour characteristics, with special emphasis 
on the relationship between AR and these factors. 
Using these parameters, we performed uni- and multivariate 
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analyses. In addition, we correlated ER and PR detected 
immunohistochemically with ER and PR levels measured by a 
biochemical method based on the enzyme immunoassay 
(EIA) . 
Patients 
PATIENTS AND METHODS 
This study was performed on a group of 153 patients (mean 
age 55 years, range 29-88 years) with primary breast cancer 
who underwent either breast conserving surgery (n = 71) or 
modified mastectomy (n = 82) with axillary lymph node dis- 
section, from 1988 to 199 1 in the Dr Daniel den Hoed Cancer 
Centre (median follow-up ,46 months, range 12-73 months). 
Patients’ age and menopausal status were recorded at the time 
of primary surgery. The tumours were graded according to 
Bloom and Richardson, with minor modifications as described 
by Elston in Page and Anderson [ 191. Histological typing was 
performed following the WHO classification [20], modified 
according to Page [ 191. Only patients without signs of distant 
metastasis at the time of surgery, with known immunohistoch- 
emically determined ER, PR, and AR status and known 
follow-up were included in this study. All patients were rou- 
tinely examined every 3-6 :months during the first 5 years. In 
the follow-up period, 46 patients (30%) showed evidence of 
recurrent disease, and 25 of’these women died. 3 patients died 
without recurrent disease. 
Methods 
Biochemistry. In 133/153 cases, material was also available 
for cytosolic ER and PR assays. As described previously [ 141, 
tumou~ tissue (0.44.8 g) was pulverised and homogenised as 
recommended by the EORTC for processing breast tumour 
tissue for cytosolic ER and PR determinations. The homogen- 
ate was centrifuged for 30 min at 1OOOOOg at 4”C, and the 
supernatant fraction (cytosolic extract) was used for ER and 
PR determination by enzyme immunoassays (ER-EIA and 
PGR-EL4 kits, Abbott, Chicago, Illinois) (cut-off values 
10 fmol/mg protein). 
Zmmunohiswchemisty. The immunohistochemical methods 
used have been previously described [ 15, 161. In short, rep- 
resentative tissue samples were snap-frozen in liquid nitrogen 
and stored at -70°C until use. Proliferative activity was 
assessed with MAb Ki-6’7 (DAKO, Glostrup, Denmark). 
Cryostat sections, 4 km thick, were air-dried and fixed in 
acetone for 10 min, after which the indirect immunoperoxi- 
dase technique was used for visualising Ki-67. For immuno- 
staining of ER, PR and AR, the cryostat sections were fixed 
with formalin (4%) diluted in phosphate-buffered saline 
(PBS). Incubation was performed with the ERICA or PRICA 
kits for ER and PR, respectively (Abbott). For immunostain- 
ing of AR, the MAb F39.3 was used, specific to a unique 
epitope in the N-terminal domain of the human AR molecule 
[2 11. Specific binding of ER and PR was visualised using the 
peroxidase-antiperoxidase (PAP) technique; for AR the 
s-ABC (streptavidin-biotirt-enzyme complex) technique was 
applied. All immunostained sections were counterstained with 
Mayer’s haematoxylin for 1 min. Control sections consisted 
of known positive and negative specimens identified by ligand- 
binding assay. In addition:, for negative control sections, the 
primary antibody was replaced with PBS or non-immune 
ascites fluid. 
Quantification. The percentage of ER-, PR- and AR-posi- 
tive tumour cells was calculated by counting the number of 
positive cells in a total of 300 cells in three different areas of 
the tumour [ 161. A staining percentage of less than 10 was 
regarded as negative. 
The Ki-67 score was assessed by counting 300 cells in 
the areas with the highest proliferative activity, as described 
previously [ 151. Arbitrarily, tumours with a Ki-67 score equal 
to or over 20% were defined as tumours of high proliferative 
activity. In 5 cases, no Ki-67 could be assessed, due to 
inadequate staining results (n = 4) and loss of material (n = 1). 
Statistics. Spearman rank correlations (rJ were used to 
study associations between continuous variables. The associ- 
ations between continuous and grouped variables were tested 
using the Wilcoxon rank sum or Kruskal-Wallis tests and the 
associated trend test, when appropriate. When patients died 
of unknown causes, they counted as failures for disease-free 
survival (DFS) at time of death (n = 3). The Cox proportional 
hazards model was applied for both univariate and multivari- 
ate analyses, using the associated likelihood ratio test to test 
for differences. Cox regression analyses are summarised in 
Table 4 by the relative relapse rates. 
Relapse-free survival probabilities were calculated by the 
actuarial method of Kaplan and Meier. The log rank test for 
trend was used for curves with three ordered groups. For all 
tests, we considered a two-sided P-value of less than 5% as 
significant. Because of the relatively short follow-up period of 
the patients and, as a result the low number of events in overall 
survival, we chose to focus only on DFS. 
RESULTS 
Patient and tumour characteristics 
Patient and tumour characteristics are summarised in 
Table 1. The histological subtypes included 114 ductal, 14 
lobular, five colloid, two tubular, one cribriform, 14 mixed, 
two medullary and one metaplastic carcinomas. Of the pre- 
menopausal women with positive lymph nodes (n = 36), 27 
received adjuvant chemotherapy, 1 hormonal therapy and 8 
received no adjuvant therapy. Postmenopausal women with 
positive lymph nodes (n = 38) received adjuvant hormonal 
therapy in 10 cases, adjuvant chemotherapy in 13 cases, while 
15 received neither chemo- nor hormonal therapy. 
Corretation between ER and PR data assessed immunohisto- 
chemically and cywsolic ER and PR levels measured with EL4 
Immunohistochemically detectable nuclear ER and PR 
were present in variable percentages of the tumour cells, but 
not in stromal cells. 
The Spearman .rank correlation between data obtained 
immunohistochemically and data obtained by EL4 was 
r, = 0.66 (P < 0.0001) for ER, and r, = 0.74 (P < 0.0001) for 
PR. When dichotomised, a discordance was observed in 11 
cases for ER and in 20 cases for PR. 
Association between expression of three steroid receptors and Ki-67 
score 
The relationship between the immunohistochemical 
expression of the three examined steroid receptors is shown in 
Table 2. In 94 cases (61%), expression of all three receptors 
was observed. Interestingly, in 14 cases (9%) only AR 
expression was found. 
An inverse relationship between AR, ER and PR expression 
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Table 1. Patient and tumour characteristics 
n % 
Patients 
Premenopausal 
Postmenopausal 
Tumour 
Histology 
T 
N 
Twe 
Grade 
Biochemistry 
ER 
PR 
Immunohistochemistry 
ER 
PR 
AR 
Ki-67 
Tl 77 50 
T2 55 36 
T3 12 8 
T4 4 3 
TX 5 3 
NO 78 51 
Nl-3 49 32 
N>3 25 16 
Unknown 1 1 
Ductal 114 75 
Lobular 14 9 
Others 25 16 
I 20 13 
II 79 52 
III 54 35 
<lo 31 20 
210 102 67 
Unknown 20 13 
<lo 45 29 
>lO 88 58 
Unknown 20 13 
<lo 32 21 
210 121 79 
<lo 54 35 
SlO 99 65 
<lo 25 16 
210 128 a4 
<20 97 63 
a20 51 33 
Unknown 5 3 
153 
70 
83 
46 
54 
AR, androgen receptors; ER, oestrogen receptors; PR, progesterone 
receptors. 
Table 2. Relationship between the immunohistochemical expression 
of the three steroid receptors 
Positivity for AR 
<lO(%) 310 (%) 
ER-PR- (n=31) 17 (11) 14 (9) 
ER+ PR- (n = 23) 4 (3) 19 (12) 
ER- PR+ (n = 1) 0 (0) 1 (0.7) 
ER+ PR+ (n = 98) 4 (3) 94 (61) 
Total (n = 153) 25 (16) 128 (84) 
AR, androgen receptors; ER, oestrogen receptors; PR, progesterone 
receptors. 
and the Ki-67 score was demonstrated; a high Ki-67 score 
was significantly (P < 0.01) associated with low receptor 
values (data not shown). 
Correlation between steroid receptor expression, Ki-67 score and 
histological typing and grading 
A variable steroid receptor expression and Ki-67 score were 
found in the group of NOS ductal carcinomas (Table 3). 
Table 3. Correlation between steroid receptor expression, 45-67 and 
histological typing and grading 
Histology n ER PR AR Ki-67 
(%) (%) (%) 3 20 
(%) 
Ductal NOS 
Lobular 
Mixed 
Special types 
Colloid 
Tubular 
Cribriform 
Others 
Medullar 
Metaplastic 
Grade 
I 
II 
III 
114 75 62 84 38 
14 100 71 92 14 
14 85 64 78 29 
5 100 100 100 0 
2 100 100 100 0 
1 100 100 100 0 
2 0 0 0 100 
1 0 0 0 0 
20 100 75 95 0 
79 75 63 75 15 
54 79 39 63 66 
AR, androgen receptors; ER, oestrogen receptors; NOS, not otherwise 
specified; PR, progesterone receptors. 
Of the 17 receptor-negative tumours, 14 were NOS ductal 
carcinomas. Strikingly, 13 of these 14 cases expressed high 
(220) Ki-67 values. In addition, the 14 cases negative for ER 
and PR and positive for AR were all NOS ductal carcinomas. 
The colloid, cribriform and tubular carcinomas combined 
ER, PR and AR expression with low (< 20) Ki-67 values 
(Table 3). Figure 1 shows this variation in staining for a 
colfoid carcinoma. 
The mixed (n = 14) and lobular (n = 14) type carcinomas 
formed an intermediate group (Table 3); only one mixed type 
carcinoma lacked all three receptors and 2/14 lobular (14%) 
and 4114 mixed (29%) carcinomas expressed 320% Ki-67 
positive cells. In contrast, the medullary (n = 2) carcinomas 
combined high Ki-67 scores with the absence of steroid recep- 
tor expression, and the metaplastic carcinoma combined 
receptor negativity with a low Ki-67 score (Table 3). 
The correlation between immunohistochemically detected 
steroid receptor expression and grade is presented in Table 3. 
Grade I and II carcinomas showed a higher percentage of 
receptor-positive cases in comparison to grade III carcinomas. 
Moreover, all receptor-negative cases (n = 17) were grade III 
cancers, in 14 cases characterised by a high percentage of Ki- 
67 positive cells. 
The 54 grade III tumours consisted predominantly of NOS 
ductal carcinomas (n = 49). 
Cowelations between steroid receptors, Ki-67 and clinicalpara- 
meters 
No significant association between immunohistochemically 
detected steroid receptor expression and lymph node status 
was observed. A significant correlation was seen for ER and 
age (rS = 0.28, PC 0.01) and an inverse relationship for 
tumour size and PR (Kruskal-Wallis associated trend test, 
P= 0.03) was seen. A borderline significant inverse relation- 
ship was found for Ki-67 score and age r, = -0.16, P= 0.05) 
and a significant rank correlation (r, = 0.21, P= 0.01) for Ki- 
67 score and lymph node status. 
DFS according to various parameters 
At 60 months, the DFS of the 153 patients was 64.7% with 
16 patients at risk. The results of univariate analysis (Table 4) 
AR Receptors and Breast Cancer 1563 
(a) Bloom & Richardson grade 
II 24119 
c 
0.60 - 
n III 2OiS4 
P 
j 0.40 - 
g 0.20 - 
v 
Fire 1. Comparison of K-67 and androgen receptor (AR) 
immunostaining of frozen sections of the same colloid breast 
carcinoma (magnification x40). (a) Only few tumour cells 
(darker nuclei) show positive staining of Ki-67. (b) Positive 
nuclear staining (darker nuclei) for AR is present in the 
majority of tumour cells. 
I I I I I 
0 12 24 36 48 
Disease-free survival (months) 
(b) Nodal status 
” L 
0 12 24 36 48 
Disease-free survival (months) 
Figure 2. (a) Disease-free survival curve stratified according 
to grade (P=O.Ol). (b) Disease-free survival curve stratified 
according to lymph node status (P= 0.02). 
Table 4. Cox t&variate and multivariate analysis in 147* patients with primary breast cancer 
Variable HRt 
Univariate 
95% c1* 
Multivariate (initial model) Multivariate (final model) 
P HR 95% CI P HR 95% CI P 
P-Q 
Nodal status 
I-311 
>3 
IH-ERI 
IH-PRY 
IH-ART 
BR§ 
Ki-677 
2.08 1.44-2.99 0.000 1.79 1.19-2.69 0.005 1.69 1.14-2.51 0.009 
1.37 0.68-2.76 1.46 0.69-3.11 
3.36 1.63-6.91 0.004 2.64 1.16-5.98 
0.43 0.23-0.81 0.008 0.40 0.14-1.14 
0.61 0.34-1.08 0.091 1.85 0.71-4.80 
0.50 0.25-0.98 0.043 0.65 0.27-1.57 
1.79 1.12-2.86 0.014 1.20 0.66-2.19 
1.79 1.00-3.22 0.052 1.05 0.51-2.17 
1.53 0.75-3.09 
0.067 2.62 1.2S5.71 0.052 
0.087 0.39 0.21-0.74 0.004 
0.205 - _ 
0.337 _ - 
0.544 _ _ _ 
0.902 _ _ _ 
*5 patients tumour size unknown and 1 patient nodal status unknown; trelative hazard rate; *confidence interval; §test for trend; lltested versus 
node-negative; ndichotomised. 
IH, immunohistochemically detected; BR, Bloom & Richardson grade; AR, androgen receptors; ER, oestrogen receptors; PR, progesterone 
receptors. 
indicated an increased risk of relapse for patients with larger Figure 4 gives an indication of the DFS according to the 
turnours, with high grade tumours (Figure 2a) and with more various immunohistochemically determined receptor combi- 
than three lymph nodes affected (Figure 2b). Similar findings nations. For DFS, the patients with ER+, PR+, AR+ turnours 
were observed when patients were stratified according to ER had the best prognosis, and the group with a combination of 
positivity (P= 0.008), AR expression (P= 0.043) and Ri-67 negative AR, ER and PR had the worst prognosis (P= 0.026), 
score (I’= 0.052). Not surprisingly, ETA-ER showed a similar but the number of patients was low (n = 17). 
correlation with DFS as did immunohistochemically detected The results of the Cox regression analysis are shown in 
ER (Figure 3). Table 4. Relative hazard rates (HR), the 95% confidence 
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E 0.60 - .l 
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.; 0.40 - 
‘3 
E - EIA 2 0.20 - 
U ------ Immunohistochemistry 
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0 12 24 36 48 
Disease-free survival (months) 
Figure 3. Disease-fkee survival curve for oestrogen receptors 
(ER) according to the method of detection. 
f-l- _______ 
0.60 - L--- 
n. 
P 
‘2 0.40 - - AR+ ER+ PR+ (24194) 
3 ------AR+: ER+ PR-/ER- PR+/ER- 
s 0.20 - 
PR- (1 l/34) 
u - - -AR-: ER+ PR-/ER+ PR+ (3/S) 
-AR- ER- PR- (8/17) 
I I I I I 
0 12 24 36 48 
Disease-free survival (months) 
Figure 4. Disease-free survival cuwes for patients with 
tumours of diierent oestrogenlprogesteronelandrogen recep- 
tor (ERKWAR) phenotypes (P= 0.026). Numbers in parenth- 
eses show failures/total amount of patients in each group. 
intervals (95% CI) and P values are given for both the uni- 
variate and multivariate analyses. The results of both the 
initial and final multivariate models are shown. The addition 
of adjuvant therapy, which was not statistically significant in 
the univariate analysis, had no influence on the estimations of 
the initial model, It appeared that tumour size and nodal 
status were the major prognostic factors, with ER status 
showing an additional prognostic value. Given these factors, 
the others showed no statistically significant associations in 
the final model. Estimations of the relative HR of tumour size 
(HR 1.70, 95% CI 1.15-2.51) and immunohistochemically 
detected ER (HR 0.36, 95% CI 0.19-0.69) were not influ- 
enced by adding adjuvant therapy as an indicator variable to 
the final model as compared to Table 4. 
DISCUSSION 
In recent years, the EIA has become an alternative method 
to the conventional dextran-coated charcoal (DCC) assay. 
Like others [22, 231 we found good correlation (P < 0.0001) 
between values obtained by EIA and those using immunohis- 
tochemistry. In addition, the prognostic impact of ER/PR 
detected by either method was similar (Figure 3). The 
observed discrepancies between EIA and immunohistochem- 
ical determination may be partly related to variations in the 
proportion of tumour tissue in the specimens examined, and 
partly to the presence of receptor-positive benign epithelium 
in EIA samples, resulting in false positive ER and PR values. 
Loss of antigenicity due to material processing, especially in 
the case of the known labile PR, may give an additional 
explanation for the discordances. No biochemical data for AR 
were available for this material, but Ruizeveld and associates 
[24] observed that immunoreactivity with this antibody was 
generally consistent with earlier biochemical and autoradio- 
graphical data. As primary tumours are of increasingly smaller 
size at primary surgery, due to breast cancer screening pro- 
grammes, immunohistochemical measurements of steroid 
expression may, in the future, become an acceptable alterna- 
tive to the binding assay, particularly as monoclonal steroid 
receptor antibodies for use on paraffin sections have become 
available. 
The inverse relationship of Ki-67 positivity with ER, PR 
and AR expression was similar to the results obtained in other 
studies for ER and PR [lo, 25, 261. However, Wintzer and 
associates [27] found no correlation between Ki-67 and ER 
status, and an inverse relationship between Ki-67 and PR, 
Gasparini and associates [28] made the opposite observation. 
These controversies may partly be explained by differences in 
the assays used and partly by differences in cut-off levels. Isola 
[29] correlated AR with proliferation as determined by the 
S-phase fraction, but found only a weak inverse association. 
The relationship between pure histological parameters, such 
as typing, grading and the biological behaviour of breast 
carcinomas, has already been emphasised [l-5]. As the 
aggressiveness of a tumour may also be reflected by the 
presence or absence of a number of other tumour character- 
istics, it seemed logical to relate the histological parameters to 
these markers. In agreement with an earlier study [15], we 
found that the Ki-67 defined proliferation index was related 
to particular types of breast cancer (see Table 3), and that 
most cases with high Ki-67 positivity were found in the group 
of NOS ductal carcinomas. No significant correlation was 
demonstrated between either Ki-67 expression or steroid 
receptor expression and grade. Yet all steroid receptor nega- 
tive tumours (n = 17), that is AR-, ER-, PR-, appeared to be 
grade III tumours. Moreover, 14 cases of this group appeared 
to be NOS ductal carcinomas and 13 demonstrated high 
(2 20) Ki-67 activity. These findings emphasise the view 
that lack of all three steroid receptors, combined with high 
proliferative activity and grading, are associated with a more 
aggressive tumour behaviour. This is substantiated by the 
DFS data (Figure 4). In contrast, and in line with published 
results [l-5, 251, we found that the colloid, tubular and 
cribriform tumours combined steroid receptor positivity, 
including AR, with low Ki-67 values and low grading 
(Table 3). In addition, consistent with the view that the group 
of mixed and lobular carcinomas represent a group of tumours 
with intermediate prognosis, we observed that only one of 28 
mixed and lobular type carcinomas lacked all three steroid 
receptors (Table 3) and only six of 28 contained 220% Ki-67 
positive tumour cells. The same relationship was found with 
respect to grading: only two of 28 mixed and lobular type 
carcinomas were grade III tumours. 
Teulings and associates [30] stated that the positive 
response to treatment with high-dose progestin (megestrol 
acetate) in a group of patients with metastatic breast cancers 
was determined by the AR level. Moreover, Hackenberg and 
colleagues [3 l] demonstrated in vitro that the progestin med- 
roxyprogesterone acetate inhibits proliferation of a ER- and 
PR-negative cancer cell line via AR. Therefore, AR positivity 
may have additional therapeutic consequences, particularly in 
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the group of carcinomas with high proliferative activity, and 
with the presence of only the AR sex steroid receptor, as was 
observed for 14 NOS ductal carcinomas. Unfortunately, in 
our series, the number of patients receiving hormonal treat- 
ment for advanced disease was too small to study this relation- 
ship. 
The prognostic impact of tumour size, lymph node status, 
ER, AR, Ki-67 and grade in univariate analysis emphasises 
the importance of these parameters. In the multivariate analy- 
sis, we confirmed [6, 261 that lymph node status, tumour size 
and ER expression were the only independent prognostic 
factors and that neither AR nor Ki-67 offered additional 
discriminating ability. 
In contrast to the large studies of Dixon and associates [2] 
and Pereira and associates [5], our study included a relatively 
small group of 34 patients with non-ductal carcinomas. 
Consequently, a reliable statistical analysis of these subsets of 
breast cancers was not possible. Nevertheless, we feel that our 
results emphasise the implortance of histological typing and 
grading of individual turnours. Moreover, they indicate that 
these histological parameters in combination with a few com- 
mon cell biological parameters, including AR, may help in 
the initial selection of high- and low-risk patients. Further 
refinement in choice of treatment for each individual patient 
may then be realised by using these parameters. 
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